155 results about "Immune complex" patented technology

The invention provides an immunodetection method of a multi-index immune checkpoint detection kit, which belongs to the technical field of immunodetection and comprises three main stages of sample preparation, immune reaction and data analysis. The method comprises the following steps: firstly, carrying out centrifugal separation to obtain a plasma sample, and preparing a fluorescent microsphere coupled capture antibody and biotin labeled detection antibody compound; then carrying out immune reaction, forming a sandwich type immune complex through specific binding, and adding streptavidin marked by phycoerythrin for signal amplification. Detecting a fluorescence signal by adopting a flow cytometer to obtain an original data matrix; a contribution feature vector, a utility feature vector and an expression feature matrix are extracted through a feature decomposition algorithm, and a deep learning model of a total-score-total structure is established for data analysis. Finally, a detection report containing a quantitative result, an importance score and reliability evaluation is generated, and the technical problem that in the prior art, the analysis accuracy of a multi-index immune checkpoint detection result is insufficient is solved.

The invention discloses a confinement composite nano-enzyme enhanced electrochemiluminescence immunosensor for detecting tumor necrosis factors and a construction method and application of the immunosensor. The immunosensor is a three-electrode system, and liquid to be detected contains luminol; wherein the working electrode is obtained by covalently immobilizing a tumor necrosis factor specific antibody after an SNF epoxy modified electrode is subjected to confinement of Ni (OH) 2-CeO2 composite nano-enzyme and then closing a non-specific site. The Ni (OH) 2-CeO2 composite nano-enzyme is confined in a nano-channel, the Ni (OH) 2-CeO2 composite nano-enzyme and the nano-channel can synergistically accelerate the process of an oxygen reduction reaction, the modification stability of the nano-enzyme is effectively improved, and a formed immune complex causes increase of interface resistance and steric hindrance of a sensing electrode to cause signal reduction; therefore, high-sensitivity detection of the tumor necrosis factor is realized, and the constructed sensor has the advantages of low detection limit, wide detection range and the like, and is very suitable for being widely applied to the fields of auxiliary clinical diagnosis, large-scale screening, health monitoring and the like.

A reagent combination, a kit, a detection system and a detection method for detecting a small molecule substance. In the condition that a solution to be tested does not contain or contains a small amount of the small molecule substance, an antibody binds to a substrate protein conjugate to form an immune complex, a stem-loop structure is generated by means of a complementary pairing among a plurality of nucleic acid molecules, a first fluorescent group excites a second fluorescent group to emit a second fluorescence on the basis of fluorescence resonance energy transfer, and the content of the small molecule substance is calculated. In the condition that the solution to be tested contains a large amount of the small molecule substance, the immune complex and the stem-loop structure cannot be formed, and the second fluorescent group cannot emit the second fluorescent.

The invention discloses a biochemical immunodetection device and a biochemical immunodetection method for ursodesoxycholic acid reduzate, and belongs to the technical field of ursodesoxycholic acid reduzate detection. The ursodesoxycholic acid reduzate detection device comprises a detection box and a lifter at the bottom of the detection box, a dissolution preparation part and a centrifugal part are arranged in the detection box, and the dissolution preparation part can fully dissolve an ursodesoxycholic acid reduzate-containing medicament; the centrifugal part is used for carrying out precipitation separation on the dissolved medicament; the detector can accurately collect fluorescence signals of the immune complex; according to the ursodesoxycholic acid reduzate detection device, the integrated operation of detection test tube fixing, cover opening and transferring, medicament adding, cover closing and plug sealing and dissolving is achieved, the steps of automatic medicament filling, sealing and the like are achieved, the medicament preparation efficiency is greatly improved, efficient and accurate detection of ursodesoxycholic acid reduzate is further achieved, and the detection efficiency is improved. And complex and tedious manual operation is avoided, and the situation that the sample is easily polluted by manual operation is avoided.

The invention provides a method for rapidly detecting fluorescently-labeled allergens for hygienic products, and relates to the technical field of detection of hygienic products. The rapid fluorescently-labeled allergen detection method for the hygienic products comprises the following steps: combining a fluorescently-labeled substance with an allergen specific antibody through a chemical coupling method to form a stable fluorescently-labeled antibody compound; fixing the fluorescence labeled antibody on the surface of a reaction chamber of a micro-fluidic chip; introducing a hygienic product sample or an extract thereof into the chip, and combining the hygienic product sample or the extract thereof with the fixed fluorescently-labeled antibody to form an'allergen-antibody-fluorescently-labeled 'immune complex; a detection area is irradiated by an excitation light source, fluorescence intensity is monitored in real time by a photoelectric sensor, and a detection result is generated by combining a data analysis module. According to the invention, the rapid and high-sensitivity detection of allergens in hygienic products is realized by combining a fluorescence labeled antibody with a microfluidic technology.

The present disclosure concerns a microfluidic method of assaying antibody secreting cells (ASCs), comprising the steps of isolating ASCs within droplets such that each droplet encapsulates only one ASC; incubating the droplets of step a) to accumulate antibodies within the droplets; picoinjecting virus into the droplets of step b) to form immune complex droplets; picoinjecting host cells into the immune complex droplets to form neutralised droplets and infected droplets; and sorting the infected droplets from the neutralised droplets, b based on infection of the host cells by the virus, to assay the ASCs within the neutralised droplets. The present disclosure also concerns a microfluidic platform thereof.

A method for quantifying at least a first glycosylated analyte having a first glycan moiety and a first protein moiety, in a sample using an immunoassay, includes contacting the sample with a plurality of first magnetic particles, and a first antibody or an antigen-binding fragment thereof specific for said first protein moiety, labelled with a reactive enzyme; allowing the first magnetic particles to capture the first glycosylated analyte; allowing the first antibody or the antigen-binding fragment thereof to form a first immunocomplex with the captured first glycosylated analyte; separating captured analytes from any uncaptured analytes and unbound antibodies or antigen-binding fragments thereof; adding a first substrate and allowing it to react with the reactive enzyme of the labelled first antibody; measuring the intensity of the first detectable signal; and correlating the measured intensity of the first detectable signal to the quantity of the first glycosylated analyte in the sample.

The invention provides an aldosterone antigen binding molecule and application thereof, and relates to the technical field of biology. The aldosterone antigen binding molecule is selected from a first antigen binding molecule containing CDR sequences as shown in SEQ ID NO.1 and SEQ ID NO.2 or a second antigen binding molecule containing CDR sequences as shown in SEQ ID NO.3 and SEQ ID NO.4. The aldosterone antigen binding molecule can bind an aldosterone antigen, and can be used for a method or a product for detecting aldosterone based on an immunological principle; the first antigen binding molecule and the second antigen binding molecule can also form an immune complex with a double-antibody sandwich structure with aldosterone, so that aldosterone is detected by a double-antibody sandwich principle.

The invention relates to an SERS (Surface Enhanced Raman Scattering) immune probe and a preparation method thereof as well as an SERS immune detection method and application thereof. The preparation method of the SERS immune probe comprises the following steps: (1) synthesizing Pd-Au-Ag NCs: taking a silver nanocube as a sacrificial template, and preparing the Pd-Au-Ag NCs through a couple replacement reaction; and (2) modification: marking 4-mercaptobenzoic acid on the surface of the Pd-Au-Ag NCs, and coupling anti-human IgG (Immunoglobulin G) to obtain the SERS immune probe. According to the SERS immune probe and the preparation method thereof as well as the SERS immune detection method and application thereof, the targeted SERS immune probe is prepared, porous silicon for forming an immune substrate by fixing CCP is taken as a substrate, and Anti-CCP is combined with the immune probe after the immune substrate captures Anti-CCP, so that a sandwich immune compound is formed, and the SERS immune probe is used for detecting the anti-CCP in the SERS immune probe. Therefore, the immunodetection method has excellent reproducibility and sensitivity.

Disclosed herein is a method for treating immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) with the factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof (e.g., iptacopan hydrochloride).

This invention discloses a quantitative test strip for HBV PreS1 antibody based on the AIE molecule, its preparation method, and its applications, relating to the fields of molecular biology, immunology, and biodetection technology. The test strip includes a sample pad, a labeling pad, a nitrocellulose membrane (NC membrane), an absorbent pad, and a base plate. The NC membrane detection line is coated with HBV PreS1 antigen to capture PreS1 antibodies in the sample. The labeling pad contains an immobilized Anti-Human IgG antibody conjugated to the AIE molecule, which binds to the PreS1 antibodies in the sample to form an immune complex. The test strip of this invention enables rapid detection of PreS1 antibodies and achieves enhanced fluorescence in the detection results. Combined with a fluorescence reader or fluorescence card reader, the detection results can be digitally and quantitatively analyzed. It is simple to operate, rapid in detection, and significantly improves detection sensitivity and enables quantitative analysis.

Aspects of the disclosure provide for devices and methods of use thereof for detecting the presence of 14-3-3η protein in capillary blood samples from subjects suspected of having or at risk of developing arthritic conditions. In an example, a method includes obtaining a capillary blood sample from such a subject, and applying the capillary blood sample to a lateral flow device under conditions sufficient for formation of an immunocomplex comprising an immobilized anti-14-3-3η antibody coupled to a 14-3-3η protein that is further coupled to a labeled anti-14-3-3η antibody, wherein formation of the immunocomplex, and visualization thereof, is indicative of the arthritic condition.

In certain embodiments, the present invention provides a method for detecting an anti-drug antibody (ADA) in a sample, comprising: a) pre-treating the sample at a high temperature to dissociate the ADA: drug immune complex in the sample; b) isolating the ADA from the sample by a matrix; c) retrieving the ADA from the matrix using a buffer, and d) detecting the ADA in a cell-based assay or an in vitro assay.

The invention belongs to the technical field of genetic engineering antibodies, and particularly relates to an antibody for non-competitive detection of aflatoxin B1 and application of the antibody. The antibody comprises a nano antibody of an anti-aflatoxin B1 antigen-antibody immune complex and a monoclonal antibody of the anti-aflatoxin B1; the amino acid sequence of the nano antibody of the anti-aflatoxin B1 antigen-antibody immune complex is as shown in SEQ ID NO. 1; the monoclonal antibody for resisting aflatoxin B1 comprises a heavy chain and a light chain; the amino acid of the heavy chain is as shown in SEQ ID NO.10, and the amino acid of the light chain is as shown in SEQ ID NO.11. The antibody for non-competitive detection of aflatoxin B1 provided by the invention is low in cost, can be prepared on a large scale through a prokaryotic expression system, is simple and convenient to prepare, has strong operability, and can be applied to non-competitive immunological analysis of aflatoxin B1.

Described herein are methods of treating immune complex mediated membrane proliferative glomerulonephritis (IC-MPGN) with a factor B inhibitor ipropam or a pharmaceutically acceptable salt thereof, e.g., ipropam hydrochloride.

Novel binding molecules comprising humanized antibodies, fragments, variants, and derivatives thereof, as well as compositions, methods, and kits comprising the same, are described, wherein the binding molecules specifically bind to FX1 and FX1a. The binding molecules are capable of binding to the factor X1A2 domain and forming immune complexes, thereby disrupting the contact activation molecule complex without affecting the activity or activation of hemostatic factor XI. The binding molecules disclosed herein are suitable for safely inhibiting thrombosis and inflammation without impairing hemostasis. Thus, the binding molecules, compositions, methods, and kits provided herein are intended for treating diseases and conditions, particularly those associated with thrombosis and inflammation. In addition, polynucleotides encoding the binding molecules disclosed herein, vectors comprising the polynucleotides, and host cells for producing the polynucleotides are also provided.

The application relates to a preparation method and application of a sandwich type photoelectrochemical immunosensor based on a Bi2S3 / BiOCl composite material, and belongs to the field of novel functional materials and biosensing detection technology; the Bi2S3 / BiOCl composite material is used as a base material, and visible light is used as a light source to obtain a photoelectric current; the two components of the base material are well matched in bands, greatly improving photoelectric conversion efficiency, so that a large output signal is obtained; different concentrations of the NSE solution to be measured result in different amounts of immune complexes, further resulting in different degrees of influence on photoelectric signals; the sensor shows high sensitivity, a wide detection range and a low detection limit to target objects, can realize rapid and sensitive determination of NSE in human serum, and has great application value for judging diseases of patients in the clinic.

An artificial immune complex (IC) free in solution, the artificial IC comprising a nucleic acid (NA) folding comprising stapled NA strands, the NA folding having an outer surface patterned with addressable sites and epitopes bound to the addressable sites and displayed in three dimensions for recruiting antibodies free in solution.

The application discloses a preparation method of a photoelectrochemical immunosensor for detecting carcinoembryonic antigen + The signal amplification strategy of liposomes and Bi2S3@BiOI heterojunction as a base material are used to successfully construct a PEC immunosensor of Bi2S3@BiOI / Ag2S ternary heterojunction, and the PEC immunosensor is used for detecting the content of carcinoembryonic antigen. Specifically, a sandwich immunocomplex is formed through specific recognition of the aptamer fixed on the magnetic beads, the aptamer labeled on the liposomes and CEA, methanol as a demulsifier is added, the liposomes are broken to release a large number of signal molecules Ag + . The released Ag + is transferred to the surface of the electrode modified by Bi2S3@BiOI to form Ag2S with a narrow band gap in situ, the ternary heterojunction of Bi2S3@BiOI / Ag2S is formed due to the existence of the energy level matching relationship, the light absorption range is expanded, the separation of photoinduced electron-hole pairs is accelerated, the photocurrent signal is enhanced, and the purpose of signal amplification is achieved.

Compositions, kits, systems, and methods for determining a total TSH concentration in a biological sample and / or determining the presence, severity, and / or predisposition of thyroid disease and / or pituitary disorder in an individual are disclosed. The compositions, kits, systems, and methods utilize at least three antibodies or antigen-binding fragments thereof that specifically bind to TSH, wherein at least one of the three antibodies or antigen-binding fragments thereof specifically binds to a TSH variant so that at least antibody-TSH-antibody sandwich immunocomplexes and antibody-TSH variant-antibody sandwich immunocomplexes can be formed. The methods include determining an amount of total TSH present in the biological sample based on the amount of the two sandwich immunocomplexes formed.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The invention discloses a preparation method and application of a clothianidin fluorescent test strip, belongs to the technical field of agricultural detection, and solves the problems that the existing bombyx mori pesticide poisoning detection sensitivity is low, and the clothianidin residue concentration cannot be quickly judged. According to the method, a nitrocellulose membrane is prepared, a detection line is coated with a clothianidin-BSA antigen, and a quality control line is coated with an anti-mouse IgG antibody; when the fluorescent pad is prepared, carboxylated fluorescent microspheres and an anti-clothianidin antibody are coupled to form a labeled probe; when the test strip is assembled, the nitrocellulose membrane, the fluorescent pad, the sample pad and the absorbent paper are stacked and fixed on the bottom plate to form a chromatography structure. Clothianidin in a sample is combined with the labeled probe to form an immune complex, chromatography migrates to the detection line to be competitively combined with clothianidin-BSA antigen, the uncombined probe is captured and develops color, and the quality control line develops color through an anti-mouse IgG antibody. The test strip is used for rapidly detecting clothianidin residues in mulberry leaves and bombyx mori bodies, the sensitivity reaches 0.02 mg / L, pesticide poisoning events can be effectively prevented, and safe production of the sericulture industry is guaranteed.

The present disclosure provides, in part, a polymeric complex comprising: (i) an immunocomplex comprising: (a) a cytokine; and (b) a soluble cytokine-binding protein; and (ii) a block copolymer disclosed herein (e.g., a block copolymer represented by Formula (I)).

Provided is a method for determining the likelihood of the onset of IgA nephropathy or the activity of the IgA nephropathy by means of a liquid biopsy of blood other than a highly invasive kidney biopsy or conventionally used proteinuria or hematuria. The present invention is a method for determining the likelihood of the onset of IgA nephropathy or the activity of the disease in a subject animal, said method comprising the steps of: (a) measuring an IgA nephropathy marker protein contained in an IgA immune complex in a blood sample collected from the subject animal; and (b) determining the likelihood of the onset or the activity of the IgA nephropathy in the test animal on the basis of the amount of the IgA nephropathy marker protein, which is a protein contained in an IgA immune complex, measured in the step (a), the IgA nephropathy marker protein being a protein contained in an IgA immune complex, and the IgA nephropathy marker protein being a protein contained in an IgA immune complex. The content of the IgA immune complex in the group of IgA nephropathy patients is greater than the content of the IgA immune complex in the group of healthy persons.

The application discloses a kind of lipoprotein detection reagent and lipoprotein detection method, it is related to biochemical detection technical field, the lipoprotein detection reagent includes R1 reagent and R2 reagent, wherein, the R1 reagent includes anti apolipoprotein B antibody, the R2 reagent includes latex microsphere coated with lipoprotein specificity antibody. Wherein, anti apolipoprotein B antibody can preliminarily enrich target lipoprotein and form immune complex to amplify detection signal, and lipoprotein specificity antibody can specifically recognize target protein and form immune complex-lipoprotein specificity antibody-latex microsphere complex, further amplify detection signal, significantly improve the detection sensitivity of reagent.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

Provided herein is a vaccination composition that comprises a recombinant immune complex (RIC) that includes an immunoglobulin heavy chain; an epitope tag, wherein the immunoglobulin heavy chain binds the epitope tag; and at least a fragment of a herpes simplex virus (HSV) type 2 glycoprotein D (HSV2 glycoprotein D). Related methods, recombinant vectors, and other aspects are also provided.

The invention discloses a five-order magnetic separation cleaning method for chemiluminescence immunoassay, which is realized through a magnetic separation device, and comprises the following steps: under the action of a rotary driving mechanism, a driving disc rotates by a certain angle each time, reaction cups on the driving disc alternately enter a suction and injection position and an avoidance position, and after the driving disc rotates by 360 degrees, the reaction cups are separated from the suction and injection position; the reaction cup completes a complete magnetic washing process once, and before the reaction cup reaches the suction and injection position opposite to the substrate needle, the substrate needle spits the substrate to the water receiving tank at the avoiding position twice. The magnetic separation device is simple in structure, small in size, low in cost and low in failure rate, five-order magnetic separation is adopted, and immune complexes are fully cleaned; the reaction cup clamping holes in the driving disc are distributed at intervals, and gaps among the reaction cup clamping holes can be used for empty injection of substrates, so that the substrates can be injected into the water receiving tank before formal injection of the substrates, and the problem of variation of first hole results of the substrates is solved.

The invention discloses a sandwich immunomagnetic relaxation switch sensor based on magnetic separation and Cu < 2 + > mediation as well as a preparation method and application thereof. The preparation method comprises the following steps: reacting dopamine under an alkaline condition to obtain polydopamine nanoparticles; covalently binding active groups on the surfaces of the polydopamine nanoparticles with amino groups of an antibody to obtain a polydopamine-antibody conjugate; mixing the aminated ferroferric oxide magnetic beads with an activated antibody solution to carry out a coupling reaction, and then carrying out cleaning, magnetic separation and closing to obtain a magnetic nanoparticle-antibody conjugate; and mixing the magnetic nanoparticle-antibody conjugate, the antigen solution and the polydopamine-antibody conjugate, and continuously reacting to obtain the sandwich immune complex. The sandwich immune complex prepared by the invention can be used as a sensor to realize efficient antibody fixation and chelating adsorption of paramagnetic Cu < 2 + > to regulate and control a magnetic relaxation signal, is combined with a magnetic separation technology to be used for quantitative determination of protein in a complex matrix, and is sensitive in detection and short in detection time.

The invention provides a separated nucleic acid molecule. The nucleotide sequence of the separated nucleic acid molecule is shown as SEQ ID NO. 1. The invention also provides an antibody coded by the nucleic acid molecule. The invention also provides a carrier which contains the nucleic acid molecule. The invention also provides a method for producing the antibody. The method comprises the following steps: transfecting antibody expression plasmids in competent cells, culturing, collecting cell supernatant, centrifuging to remove precipitate, purifying antibody protein, collecting eluent, and concentrating to obtain the antibody. The invention also provides an application of the antibody, the carrier or the pharmaceutical composition in preparation of drugs for treating autoimmune diseases. The antibody disclosed by the invention can be specifically combined with FcRn and Fc gamma Rs, is a potent inhibitor for FcRn-mediated IgG recirculation and Fc gamma R-dependent immune complex activation, is a therapeutic drug for autoimmune diseases, and has huge potential.